Close Menu

NEW YORK – Mammoth Biosciences said on Wednesday that it has signed a collaboration deal with the consumer healthcare arm of pharmaceutical company GlaxoSmithKline to develop a CRISPR-based SARS-CoV-2 diagnostic test for use by consumers at home and healthcare providers in clinics.

The partners plan to use Mammoth's DNA Endonuclease-Targeted CRISPR Trans Reporter (DETECTR) platform, which can identify and signal the presence of viral RNA in a sample obtained through a nasal swab.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.